Cheaper breast cancer drug copy put to the test – but trial ends early
NCT ID NCT06038539
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tested a biosimilar called PERT-IJS against the original drug Perjeta, both given with standard chemotherapy, in women with early or locally advanced HER2-positive breast cancer. The goal was to see if the biosimilar works just as well at eliminating cancer before surgery. The trial was terminated early and enrolled only 55 participants, so the findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PERT-IJS (a biosimilar to pertuzumab) plus trastuzumab and chemotherapy (carboplatin and docetaxel)
- What this could lead to
- If successful, this could show that a more affordable biosimilar works as well as the original drug for treating HER2-positive breast cancer before surgery.
- What could go wrong
- The trial was terminated early with only 55 participants, so results are limited. Biosimilars may not always match the original drug's effectiveness or safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR NEGATIVE HER2 POSITIVE EARLY BREAST CANCER OR LOCALLY ADVANCED BREAST CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chopda Medicare & Research Centre Pvt. Ltd,
Nashik, 422005, India